The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Adagio” or the “Company”) (NASDAQ: IVVD) common stock between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). Adagio investors have until April 3, 2023 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

On December 14, 2021, Adagio disclosed that its COVID-19 treatment and prevention product, ADG20, was 300 times less effective at neutralizing the Omicron variant than it was against other variants, despite previous assurance of the efficacy against Omicron.

On this news, Adagio’s stock price fell $27, or 78.8%, to close at $7.26 per share on December 14, 2021, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (2) that defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; (3) that ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Adagio common stock during the Class Period, you may move the Court no later than April 3, 2023 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased Adagio common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005070/en/

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors